Antibody drug conjugates continue to be a robust area for research and dealmaking, and Eli Lilly’s latest move in this space is the acquisition of CrossBridge Bio, a preclinical startup with technology and a lead program that could bring patients more powerful cancer treatments.
Lilly is paying up to $300 million for CrossBridge, according to deal terms announced Tuesday. The companies did not provide a financial breakdown, other than to say the sum spans an upfront payment and a subsequent payment for a development milestone that was not disclosed.
In an ADC, a toxic drug payload is delivered to a tumor by leveraging the targeting ability of an antibody. Houston-based CrossBridge develops ADCs engineered to carry two drug payloads. This approach is intended to provide a wider therapeutic index, the dose range that balances safety and efficacy. It can also address mechanisms that cancers use to develop drug resistance.
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
Lead CrossBridge program CBB-120 is designed to target TROP2, a protein expressed by many solid tumors including cancers of the breast and lungs. This target is already addressed by Trodelvy, a blockbuster ADC marketed by Gilead Sciences for treating certain breast and bladder cancers. Trodelvy’s drug payload inhibits topoisomerase 1, an enzyme that’s active in rapidly dividing cancer cells. CrossBridge’s dual-payload ADC carries a topoisomerase 1 inhibitor and an inhibitor of ATR, a protein that promotes the survival of cancer cells. An investigational new drug (IND) application for CBB-120 is expected this year.
CrossBridge was founded in 2023 based on ADC technology developed by Kyoji Tsuchikama, a professor of medicinal chemistry at the University of Texas Health Science Center at Houston. In 2024, CrossBridge announced $10 million in seed financing led by TMC Venture Fund and CE-Ventures. Last year, the Cancer Prevention and Research Institute of Texas awarded CrossBridge a $15 million grant to support IND-enabling studies for CBB-120.
“We look forward to seeing how Lilly advances our new generation of dual-payload antibody-drug conjugates, including CBB-120, with the potential to meaningfully improve outcomes for patients with limited treatment options,” CrossBridge co-founder and CEO Michael Torres said in a prepared statement. “At CrossBridge Bio, we believe our dual-payload ADC platform is uniquely positioned to be transformative in oncology.”
Lilly already has a presence in ADC R&D. Its clinical-stage pipeline includes sofetabart miptecan, an ADC designed to target folate receptor alpha to treat platinum-resistant ovarian cancer. This drug is currently in Phase 3 testing. In 2023, Lilly purchased Germany-based ADC developer Emergence Therapeutics. A Nectin-4-targeting ADC from the deal, ETx-22, is in preclinical development for urothelial cancer, according to Lilly’s annual report.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
Lilly’s CrossBridge acquisition is the latest in a recent flurry of ADC business deals. Last week, Gilead announced a $3.15 billion deal to buy Tubulis, a clinical-stage ADC developer with platform technologies that yield ADCs with better stability and larger capacity to carry more drug payload. The week also included mega-financing rounds from startups Sidewinder Therapeutics and Stipple Bio, each developing new approaches to improving the targeting ability of ADCs.
Photo by Flickr user Paul Sableman via a Creative Commons license